[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
Aug 2011

Complete Response of Metastatic Malignant Hidradenocarcinoma to Capecitabine Treatment

Author Affiliations

†Deceased

Author Affiliations: Departments of Medicine (Dr Lerner), Dermatology (Drs Beckford, Ugent, Goldberg, and Demierre), and Otolaryngology –Head and Neck Surgery (Dr Jalisi), Boston University School of Medicine, Boston, Massachusetts.

†Deceased

Author Affiliations: Departments of Medicine (Dr Lerner), Dermatology (Drs Beckford, Ugent, Goldberg, and Demierre), and Otolaryngology –Head and Neck Surgery (Dr Jalisi), Boston University School of Medicine, Boston, Massachusetts.

Arch Dermatol. 2011;147(8):998-999. doi:10.1001/archdermatol.2011.210

Malignant hidradenocarcinoma is a rare locally aggressive eccrine tumor with high metastatic potential.1 Few studies have reported effective therapy for this malignant neoplasm, and in none has a complete response been observed.2,3 We describe a patient with unresectable metastatic malignant hidradenocarcinoma who experienced a durable complete clinical and radiologic response after 3 months of oral capecitabine treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×